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Abstract. 
Artemisinin combination therapy is recommended for the treatment of multidrug resistant Plasmodium 
falciparum and Plasmodium vivax. In March 2006, antimalarial policy in Indonesia was changed to a unified 
treatment with dihydroartemisinin-piperaquine for all species of malaria because of the low efficacy of previous 
drug treatments. In 2013, a randomized cross-sectional household survey in Papua was used to collect data on 
demographics, parasite positivity, treatment-seeking behavior, diagnosis and treatment of malaria, and 
household costs. Results were compared with a similar survey undertaken in 2005. A total of 800 households 
with 4,010 individuals were included in the 2013 survey. The prevalence of malaria parasitemia was 12% 
(348/2,795). Of the individuals who sought treatment of fever, 67% (66/98) reported attending a public provider 
at least once compared with 46% (349/764) before policy change (P < 0.001). During the 100 visits to 
healthcare providers, 95% (95) included a blood test for malaria and 74% (64/86) resulted in the recommended 
antimalarial for the diagnosed species, the corresponding figures before policy change were 48% (433/894) and 
23% (78/336). The proportion of individuals seeking treatment more than once fell from 14% (107/764) before 
policy change to 2% (2/98) after policy change (P = 0.005). The mean indirect cost per fever episode requiring 
treatment seeking decreased from US$44.2 in 2005 to US$33.8 in 2013 (P = 0.006). The implementation of a 
highly effective antimalarial treatment was associated with better adherence of healthcare providers in both the 
public and private sectors and a reduction in clinical malaria and household costs. 
INTRODUCTION 
In Indonesia, the greatest prevalence of malaria is in the eastern provinces of Nusa 
Tenggara Timur and Papua.1 Great progress has been made in reducing the burden of malaria 
with the majority (74%) of the Indonesian population residing in malaria-free areas. 
However, 12% of the population still reside in areas with a malaria incidence greater than one 
case per 1,000 per year,2 and these individuals are at increased risk of malaria associated 
anemia.3,4 Until 2006, the first line policy was chloroquine plus sulfadoxine-pyrimethamine 
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and a single dose of primaquine for uncomplicated Plasmodium falciparum malaria, and 
chloroquine plus primaquine (total dose 3.5 mg/kg over 14 days) for radical cure for 
Plasmodium vivax with the exception of infants less than 1 year of age and pregnant or 
lactating women for whom chloroquine alone was recommended.5 In 2005, clinical trials in 
Papua, Indonesia, highlighted very high levels of antimalarial drug resistance to the 
recommended treatment regimens with recrudescent P. falciparum and recurrent P. vivax 
infections exceeding 40% by day 28 after treatment.5–7 Dihydroartemisinin-piperaquine 
(DHP) was shown to be highly effective against both species.8,9 In response, national policy 
was changed in March 2006 to the fixed dose artemisinin combination therapy (ACT) of 
DHP for uncomplicated malaria due to any species of malaria.8,9 The recommendation of 
single dose primaquine for P. falciparum remained, whereas the dose of primaquine 
recommended for P. vivax was increased to a total of 7 mg/kg over 14 days. The policy also 
stipulated that antimalarial treatment should only be given after laboratory confirmation, 
which was not a recommendation before 2006. 
Before the change in policy, a cross-sectional household survey was undertaken in 2005, 
which documented that 42% of individuals reported having had a febrile illness in the 
preceding month, for which they sought treatment multiple times, often at different healthcare 
facilities.10 Only 46% of these individuals reported seeking treatment at a public provider, 
despite provision of treatment for free in the public sector. Most households reported a 
monthly income less than US$500, hence each individual’s fever episode resulted a cost of at 
least 11% of the household income.10 After policy change, the DHP was provided free of 
charge at public health facilities but was also available at a cost in the private sector. 
Changes in antimalarial policy can potentially impact the overall burden and transmission 
of malaria not only through the direct impact of switching to a more effective treatment but 
also through increasing the community’s trust in the public health care system and the 
subsequent shifts in treatment-seeking behavior. The aim of this study was to describe the 
changes in treatment-seeking behavior for fever and burden of disease in Papua after policy 
change to ACT for all species of malaria. 
MATERIALS AND METHODS 
Household surveys were conducted in Mimika Regency, southern Papua, Indonesia, in 
2005 and 2013. The methods in 2013 were based on the 2005 survey which has been reported 
previously.10 Minor differences between the questionnaires included the collection of 
household income as a range rather than a specific estimate and information on bed net use 
by individuals rather than ownership by the household. 
The demographics, malaria transmission, and health services in this region have been 
described previously.3,4,11 In brief, the district covers an area of 21,522 km2 with a population 
of approximately 120,457 in 2005 expanding to 202,350 in 2013. Most of the population 
resides in 12 districts, incorporating Timika town and the surrounding villages. The area is 
covered with thick rain forest with both coastal and mountainous areas, inhabited by a variety 
of ethnic groups which are broadly categorized as lowland Papuans, highland Papuans, or 
non-Papuans. Malaria transmission occurs throughout the year and is restricted to the lowland 
area where most of the population lives. There are three mosquito vectors: Anopheles 
koliensis, Anopheles farauti, and Anopheles punctulatus. 
Healthcare provision is provided free of charge at public providers, which includes one 
hospital, 12 Government-funded Primary Health Clinics (Puskesmas), and 10 malaria control 
clinics provided by a local mining company. In 2008, a second hospital was opened, 
providing care to approximately 100,000 patients per year. Antimalarials can also be 
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purchased in the private sector, including clinics, pharmacies, and drug stores.12 Diagnostic 
tests for malaria are available in the private sector but usually not in drug stores. 
The household sampling strategy was the same for both surveys with 800 households 
sampled using a three-stage cluster sampling procedure to identify 32 clusters of 25 
households.10,13 First, the four most populous subdistricts (Mimika Baru, Kuala Kencana, 
Iwaka, Kwamki Narama, and Wania) were chosen from the 12 subdistricts based on their 
accessibility by road from the main town of Timika and because they included the majority 
(80%) of the district’s population. The 2013 survey took place in similar geographic areas as 
the 2005 survey, but during the intervening years some of the subdistricts had been renamed. 
The 2013 survey took place in similar geographic areas as the 2005 survey, but during the 
intervening years some of the subdistricts had been renamed. Second, the number of clusters 
in each subdistrict was apportioned according to their relative populations. The houses were 
then assigned numbers based on their geographical location, and clusters of 25 houses were 
identified. 
The 2013 survey was conducted in the months of April through July, whereas the 2005 
survey was conducted between the months of July and December. Household members were 
defined as all individuals living under one roof and who ate from one kitchen. If a selected 
household was empty, the interviewer returned the next day. If still unoccupied, the next 
occupied household was sampled instead. As the recall period for the survey was fever in the 
previous month, temporary migrants who had moved into the area within the preceding 
month were excluded from the survey. 
Ethics. 
This study was approved by the Ethics Committee of the National Institutes of Health 
research and Development, Indonesian Ministry of Health and the Human Research 
(KS.02.01.2.1.2684), University of Gadjah Mada (KE/FK/763/EC), and the Ethics 
Committee of Northern Teritorry Department of Health and Community Services and 
Menzies School of Health Research, Darwin, Australia (HREC 04/47 and 10-1434). Written 
informed consent was obtained from all adult participants and parents of enrolled children. 
Data collection. 
The head of the household or another suitable adult was asked questions about the 
household and its members. Those members who were present at the time of the survey 
underwent a brief examination. Capillary or venous blood samples were collected for blood 
film examination. Symptomatic illness was defined as a history of fever in the past 24 hours 
or an axillary temperature of 37.5°C or higher when examined. Nearly all surveys were 
conducted in Bahasa Indonesian and the remaining in a local Papuan language. Individuals 
reporting a history of fever in the preceding 30 days were asked to complete a separate 
module with detailed questions on treatment-seeking if they were present. This module 
comprised questions on all of the places where they had sought treatment, whether they had 
received a blood test, whether they were prescribed antimalarials or other medicines, and any 
associated costs to the households. 
Data analysis. 
Data were analyzed using the STATA statistical software (version 14.2)14 and R (version 
3.2.3).15 A Discriminant Analysis of Principal Components was used to categorize 
households by socioeconomic status (SES) by data on reported ownership of assets.10,16 To 
ensure that sufficient time had elapsed to capture treatment-seeking behavior, those 
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individuals reporting fever starting within the preceding 2 days were excluded from the 
analysis of treatment seeking. For the use of diagnostics, laboratory tests, and antimalarial 
prescriptions, each patient–provider interaction (“visit”) was analyzed for public and private 
healthcare providers. 
Frequencies and percentages were used for the descriptive data. Percentages were 
compared using the χ2 test (χ2). Differences in outcome distributions were evaluated with the 
Mann–Whitney test. Continuous variables were compared using the Spearman’s rank for 
correlation. When less than five observations were seen in a category, categorical outcomes 
were compared using the Fisher’s Exact test. Simple logistic regression adjusted for 
clustering by households was used to calculate odds ratios (ORs) for comparisons within the 
2013 survey. For the analysis of reported fever in the past month, significant risk factors (P < 
0.05) in the univariate analysis were included in a multiple logistic regression model and 
significant interactions between age, ethnicity, and significant variables were reported. The 
2005 and 2013 surveys were compared using adjusted odds ratios (AORs) for age (0–4, 5–14, 
15+), gender, household SES, and ethnicity (non-Papuan, highland Papuan, and lowland 
Papuan). The models were adjusted for clustering by household. 
Costs were gathered in Indonesian rupiah converted into United States Dollars (US$) 
using the average exchange rates17,18 and then revised to the 2014 equivalent using the 
consumer price index for Indonesia.19 The mean cost and standard deviation (SD) per fever 
episode are reported. Direct costs included transportation for the patient and care and 
treatment, which included consultations, diagnosis, medication, overnight stay, and any other 
payments. Indirect costs included the amount of time that usual activities were reduced for 
the individual and any companions, caretakers, or substitute laborers. This time was valued 
using the mean reported wage for all. 
RESULTS 
Household characteristics. 
A total of 800 households with 4,010 individuals were included in the 2013 survey 
(Figure 1). The baseline characteristics for both the 2005 and 2013 surveys are provided in 
Table 1. In 2013, the median household size was five individuals (interquartile range [IQR] = 
4–6) with a maximum of 13 in one house. The median duration that heads of households 
reported residing at their current location was 13 years (IQR = 6–20), with 23 (3%) 
households reporting a move into that location within the previous year. In 2005, the 
household size was six individuals (IQR = 4–8) with a median duration of 9 years (IQR = 4–
15). Of the 781 households in which monthly household income was reported, 52% (403) 
estimated US$560 or less. The households were categorized into five SES groups, with the 
number of households in each group ranging from 91 to 296. While poorer households were 
more likely to grow their own crops and drink rain water, richer households were more likely 
to own motorcycles and large electrical items and drink bought water (Supplemental Figure 
1). The poorest SES group was composed of a greater percentage of Highland Papuans (32%, 
47/145) compared with 19% (35/189) of Lowland Papuans and 3% (15/465) of non-Papuans 
(P < 0.001). The estimated household general health expenditure was correlated with the 
number of individuals reporting fever in a household (ρ = 0.488, P < 0.001). 
History of fever and parasite positivity of household members. 
Of the 2,830 (71%) individuals present at the time of the interview in 2013, 41% (1,162) 
were male, 43% (1,225) were under the age of 15, and 46% (1,290) were Papuan (Table 1). 
Overall, 4% (117/2,830) of individuals reported having had a febrile illness in the preceding 
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month compared with 42% (1,631/3,896) in 2005 (AOR = 0.06, 95% confidence interval [CI] 
= 0.05–0.08, P < 0.001; Table 2). Non-Papuan participants were at a significantly higher risk 
for having had a febrile illness compared with Highland Papuans (AOR = 1.84, 95% CI = 
1.05–3.26, P = 0.035; Supplemental Table 1). 
Overall, 12% (348/2,795) of individuals who consented to blood testing in 2013 were 
parasitemic, a slight reduction from 16% (634/3,890) in 2005 (AOR = 0.83, 95% CI = 0.69–
0.99, P = 0.038). The change in prevalence was most apparent in individuals with 
symptomatic parasitemia which decreased from 5% (200/3,890) in 2005 to 1% (21/2,795) in 
2013 (AOR = 0.16, 95% CI = 0.10–0.26, P < 0.001), whereas the prevalence of 
asymptomatic parasitemia was similar in both surveys: 11% (434/3,890) in 2005 and 12% 
(327/2,795) in 2013 (AOR = 1.20, 95% CI = 0.98–1.45, P = 0.073). Individuals reporting a 
febrile illness in the past month were significantly more likely to be parasitemic in the 2005 
survey (OR = 3.81, 95% CI = 3.10–4.68, P < 0.001); however, this was not significant in the 
2013 survey (OR = 1.53, 95% CI = 0.89–2.61, P = 0.123). The prevalence of parasitemia in 
each subdistrict is presented in Supplemental Table 2. 
Treatment-seeking behavior. 
In 2013, treatment-seeking behavior was assessed in 98% (115/117) of participants 
reporting a fever in the preceding month, and in 94% (108/115) of these individuals the fever 
commenced at least 2 days before the survey (Figure 1). Individuals were more likely to take 
some form of medicine for their fever in 2013 with 92% (99/108) reporting taking medication 
compared with 76% (834/1,104) of those whose fever commenced at least 2 days before the 
survey in 2005 (AOR = 2.50, 95% CI = 1.23–5.06, P = 0.011). Of the 99 patients who 
reported taking a medication, only 1% (1) did not seek treatment outside of the home, 
compared with 8% (70/834) in 2005 (P = 0.004). In 2013, 67% (66/98) of individuals seeking 
treatment outside of the home attended a public provider at least once compared with 46% 
(349/764) in 2005 (AOR = 4.30, 95% CI = 2.54–7.28, P < 0.001). Furthermore, individuals in 
the three lower SES groups were more likely to seek treatment at a public provider at least 
once compared with those in the top two SES groups (OR = 6.10, 95% CI = 2.05–18.11, P = 
0.001); this was also apparent in 2005 (OR = 2.29, 95% CI 1.59–3.32, P < 0.001). 
Diagnosis of malaria at healthcare providers. 
Of the 100 visits to healthcare providers in 2013, 95 (95%) involved a blood test for 
malaria compared with 48% (433/894) in 2005 (AOR = 24.42, 95% CI = 9.87–65.43, P < 
0.001); Table 3. Malaria testing was positive in 92% (87/95) of cases and in one visit the 
result was not reported. Plasmodium falciparum was diagnosed in 53% (46/87) of cases, P. 
vivax in 43% (37/87), mixed infections in 3% (3/87), and Plasmodium malariae in 1% (1/87). 
The increase in likelihood of individuals being tested for malaria was most apparent in the 
private sector where 29% (148/519) of individuals were tested in 2005 compared with 97% 
(31/32) in 2013 (P < 0.001). 
Antimalarial treatment at healthcare providers. 
In 2013, an antimalarial (alone or with other medicines) was reportedly prescribed during 
88% (88/100) of visits to healthcare providers. Most of these prescriptions were given as 
tablets (95%, 84/88) with one (1%) injection and three (3%) for both an injection and tablets. 
Of the four malaria injections that were reported, two were at the public hospital and two at 
private providers. Ninety-nine percent (87/88) of antimalarial prescriptions followed a blood 
test as per clinical guidelines; all were reportedly positive. This was a significant increase 
compared with 2005 when only 61% (336/547) of prescriptions followed a blood test (P < 
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0.001). In 2013, the antimalarial treatment regimen was prescribed correctly in 74% (64/86) 
of healthcare encounters in which P. vivax, P. falciparum, or mixed infections were 
diagnosed, a significant increase from 2005 when only 23% (78/336) of individuals were 
correctly treated according to the prevailing guidelines (AOR = 15.71, 95% CI = 8.18–30.18, 
P < 0.001; Table 3). These improvements in prescribing habits were apparent in both the 
public (AOR = 15.93, 95% CI = 6.84–37.14, P < 0.001) and private sectors (AOR = 12.16, 
95% CI = 3.42–43.28, P < 0.001). 
The reported treatments prescribed for the different species are presented in Table 4. In 
2013, 95% (57/60) of patients diagnosed with malaria in a public facility were treated with 
DHP compared with 52% (14/27) of those treated at a private provider (P < 0.001). Between 
2005 and 2013, the percentage of individuals reportedly being treated with 14 days of 
primaquine for P. vivax infection (alone or mixed) rose from 9% (16/169) to 63% (25/40); 
(AOR = 37.49, 95% CI = 9.94–141.41, P < 0.001). Over the same period, the percentage of 
patients with P. falciparum reporting treatment with a single dose primaquine rose from 19% 
(31/167) in 2005 to 50% (23/46) in 2013 (AOR = 6.27, 95% CI = 2.68–14.68, P < 0.001). 
Cost burden of fever. 
In 2013, a total of 100 visits to healthcare providers were reported by 98 individuals; 
hence, nearly all patients reported requiring only one visit compared with 14% (107/764) of 
individuals who reported seeking medical care at two or more providers before the policy 
change (P < 0.001). In 2013, the mean total direct cost to the household per visit was 
US$16.8 (SD = 19.0) at a private provider and US$4.1 (SD = 14.4) at the public sector (P < 
0.001). The mean daily wage in 2013 was US$18.2 (SD = 12.5), with a total mean indirect 
cost per fever episode of US$52.5 (SD = 41.4) for adults and US$7.3 (SD = 16.4) for 
children. 
Table 5 shows the cost per fever episode resulting in treatment seeking in 2005 and 2013. 
While the direct costs were similar (P = 0.119), a significant decrease in indirect costs was 
evident from US$44.2 (SD = 51.0) before the policy change to US$33.8 (SD = 40.1) after the 
policy change (P = 0.006). In 2013, only 29% (29/99) of individuals reported that someone 
had had to cut back on their usual activities to care for them, a decrease from 77% (641/834) 
in 2005 (OR = 0.12, 95% CI = 0.08–0.20, P < 0.001). There was also a reduction in the 
number of individuals requiring a substitute laborer from 8% (66/834) in 2005 to 1.0% (1/99) 
in 2013 (P = 0.007). There was no significant difference in the proportion of individuals 
having at least one companion accompany them to seek treatment (66% (553/834) in 2005 
versus 73% (72/99) in 2013; P = 0.200). Overall, the mean cost per fever episode was 
US$41.9 (SD = 44.3) in 2013 compared with US$53.5 (SD = 65.3) in 2005 (P = 0.104). 
DISCUSSION 
The results of the household surveys undertaken before and after the implementation of 
ACT after confirmed diagnosis in Papua, Indonesia, highlight several important changes in 
treatment-seeking behavior, diagnosis of malaria, and adherence to antimalarial drugs. Only 
one individual (1%) did not seek treatment outside of the home compared with 8% in 2005 
when less efficacious treatments were available in both the public and private sectors. This 
shift in treatment seeking was associated with more individuals attending public providers at 
least once, rising from 46% in 2005 to 67% in 2013. Those from households with lower SES 
were still more likely to seek treatment at public providers than those with higher SES. 
Before the implementation of ACT, more than 40% of patients failed antimalarial 
treatment within 42 days, with almost half of these patients doing so within 7 days.5 The 
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introduction of a 3-day regimen of DHP resulted in rapid parasite clearance and symptom 
recovery with less than 5% of patients having recurrent malaria, most of which occurred after 
28 days.8 Hence, the observed changes in treatment-seeking behavior likely reflect 
community awareness of such highly effective treatments and their availability initially in the 
public sector and subsequently in the private sector. 
In parallel with the shift in where patients sought treatment, there were also significant 
changes in the way in which healthcare services were provided, particularly the treatment of 
malaria only after laboratory confirmation and adherence to antimalarial policy. Rapid 
diagnostic tests were introduced at public health facilities without microscopists in 2006–
2007 and were used for half of the outpatient visits to one of the hospitals, whereas 
microscopy remained the main diagnostic for patients requiring admission to hospital. In 
2013, individuals who attended healthcare facilities were almost twice as likely to have a 
blood test for malaria compared with those in 2005, and this was particularly prominent in the 
private sector where almost all patients were offered a blood test in 2013. Considering that 
dissatisfaction with the public sector is common20 and studies in Southeast Asia have shown 
that a large proportion of individuals seek treatment in the private sector,21,22 improvement of 
both sectors is vital to ensuring public health benefits.23 
Our findings also demonstrate that individuals diagnosed with malaria in 2013 were 3-
fold more likely to receive the recommended treatment regimen. Importantly, both the public 
and private sectors implemented the policy change to ACT, with reductions in prescriptions 
of non-ACT antimalarials apparent in both sectors. This included an 8-fold decline in 
chloroquine prescriptions. Furthermore, better prescribing practices were also observed for 
primaquine, which is encouraged as a single dose for reducing the transmission potential of 
P. falciparum and as a 14-day regimen for the radical cure of P. vivax (14 day). 
The survey results also highlight a modest fall in the prevalence of parasitemia from 16% 
to 12%, although individuals who were parasitemic were 6-fold less likely to be 
symptomatic. Furthermore, a 10-fold reduction (from 42% to 4%) was observed in those 
reporting fever in the preceding month. Before policy change, individuals reporting a recent 
fever were three times more likely to be parasitemic at the time of the survey than those with 
no recent febrile illness. Since the risk an infected mosquito bite within 28 days in this region 
is low (< 8%), the most likely explanation for this is that before 2006 treatment with partially 
effective treatment often failed to clear parasitemia by the time of the survey, whereas this 
was no longer apparent after the change in policy to highly effective treatment with ACT. By 
contrast, no reduction was observed in the prevalence of asymptomatic parasitemia between 
2005 and 2013, a likely reflection of these patients not being unwell enough to seek 
treatment.24 
The first survey was conducted between July and December, whereas the second was 
undertaken from April through July. While seasonal variation in either malaria or other 
causes of fever could therefore have influenced our observations, malaria transmission in this 
area occurs throughout the year with minimal seasonality.24 Other factors that could have 
affected our results include fluctuations in the demography. Between 2005 and 2013, the 
population grew from 120,000 to 172,000, and this was complemented with a slight increase 
in the proportion of non-Papuans, who are generally less immune. But this was countered by 
individuals reporting having lived in the area longer which would facilitate greater 
asymptomatic infections. In 2013, the only significant risk factor for recent febrile illness was 
being non-Papuan (Supplemental Table 1). Whereas in 2005 lowland Papuans, children less 
than 5 years old, and those from lower SES household were all at greater risk.10 The changes 
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in treatment-seeking behavior therefore likely reflect a complex shift in population dynamics 
coupled with the impact of better treatment regimens and healthcare provision. 
The observed changes in treatment seeking had important implications for the household 
costs incurred by malaria. While the mean cost for each febrile episode decreased from 
US$53.5 to US$41.9, reported monthly income in households increased from 60% with less 
than US$500 in 2005 to 49% with less than US$560 in 2013. Furthermore, in 2005, 
households more frequently reported multiple household members with fevers in the past 
month and those household members reported repeat visits as compared with 2013. 
Considering the decrease in symptomatic individuals who were parasite positive, it is likely 
that many of these changes in treatment-seeking behavior are a result of effective treatment. 
This study has a number of limitations. First, a degree of recall bias is likely due to the 
time between the fever episode and the survey, although this bias would be expected to be 
similar for both surveys. The 8-year gap between surveys increases confounding from other 
changes besides the policy change including demographic dynamics, such as smaller 
households, greater representation of females, and duration residing in the study area. Public 
health and malaria control activities aimed at changing behavior remained similar over this 
time period. Because of differences in the phrasing of the questionnaires, we were unable to 
explore how the use of bed nets had changed over time. As with the previous survey, many 
older male household members were not present at the time of the interviews and temporary 
migrants were excluded. 
In conclusion, the policy change in March 2006 to a unified treatment of malaria with 
DHP has had a significant impact on treatment-seeking behavior, resulting in more patients 
attending healthcare facilities where better case management was being provided. These 
changes have had a significant impact on the burden of malaria with less patients reporting 
febrile illness; however, increases were seen in asymptomatic infections. Further reduction in 
malaria and its ultimate elimination will require implementing more effective radical cure of 
P. vivax and the implementation of active case detection or presumptive interventions. 
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FIGURE 1. Flow diagram of household members, interviews, initial location of treatment taking, and whether 
they took a second treatment in 2013. 
TABLE 1 
Demographic characteristics of all household members and individuals present during surveys in 2005 and 2013 
 2005 2013 
Characteristic, n (%) 
All household 
members (N = 
5,255) 
Present 
during 
survey (N = 
3,896) 
All 
household 
members (N 
= 4,010) 
Present 
during 
survey (N = 
2,830) 
Age (years) 
 0–4 870 (17%) 820 (21%) 629 (16%) 559 (20%) 
 5–14 1,101 (21%) 824 (21%) 970 (24%) 666 (24%) 
 15+ 3,284 (62%) 2,252 (58%) 2,404 (60%) 1,604 (57%) 
 Not reported – – 7 (0.2%) 1 (0.04%) 
Sex (female) 2,409 (46%) 2,019 (52%) 2,035 (51%) 1,668 (59%) 
Pregnant (yes) 92 (2%) 87 (2%) –* 45/2,825 
(2%) 
Place of birth 
 Highland Papuan 1,494 (28%) 1,045 (27%) 733 (18%) 539 (19%) 
 Lowland Papuan 1,371 (26%) 1,024 (26%) 1,039 (26%) 751 (27%) 
 Non-Papuan 2,390 (45%) 1,827 (47%) 2,238 (56%) 1,540 (54%) 
Resided in lowlands for more than 1 year? (yes) 4,969 (95%) 3,674 (94%) 3,862 (96%) 2,711 (96%) 
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Subdistrict 
 Banti 152 (3%) 119 (3%) 0 (0%) 0 (0%) 
 Harapan and Kwamki Lama 901 (17%) 576 (15%) 111 (3%) 80 (3%) 
 Inauga 521 (10%) 405 (10%) 383 (10%) 291 (10%) 
 Kamoro Jaya 354 (7%) 273 (7%) 369 (9%) 257 (9%) 
 Kadun Jaya, Kaugapu and Pigapu 371 (7%) 286 (7%) 267 (7%) 210 (7%) 
 Limau Asri, Iwaka, Mulia Kencana and 
Naena Muktipura 136 (3%) 112 (3%) 506 (13%) 334 (12%) 
 Koperapoka 957 (18%) 729 (19%) 753 (19%) 521 (18%) 
 Timika Jaya, Kwamki and Kwamki Baru 1,407 (27%) 1,046 (27%) 989 (25%) 696 (25%) 
 Wonosari Jaya and Nawaripi 122 (2%) 98 (3%) 374 (9%) 267 (9%) 
 Karang Senang and Bhintuka 334 (6%) 252 (6%) 258 (6%) 174 (6%) 
* Not reported. 
TABLE 2 
Fever reporting in those who were present during the survey in 2005 and 2013 
 2005 2013 
Characteristic, n (%) 
Reported fever 
during previous 
month (N = 
1,631/3,896, 
42%) 
Reported fever 
starting > 2 days 
before survey and 
took treatment (N 
= 834/1,631, 
51%) 
Reported fever 
during previous 
month (N = 
117/2,830, 4%) 
Reported fever 
starting > 2 days 
before survey and 
took treatment (N 
= 99/117, 85%) 
Age (years) 
 0–4 405 (25%) 205 (25%) 23 (20%) 15 (15%) 
 5–14 306 (19%) 148 (18%) 29 (25%) 26 (26%) 
 15+ 920 (56%) 481 (58%) 65 (56%) 58 (59%) 
Sex (female) 850 (52%) 433 (52%) 63 (54%) 55 (56%) 
Pregnant (yes) 39 (2%) 23 (3%) 3/116 (3%) 3/98 (3%) 
Place of birth 
 Highland Papuan 385 (24%) 172 (21%) 14 (12%) 11 (11%) 
 Lowland Papuan 463 (28%) 183 (22%) 28 (24%) 19 (19%) 
 Non-Papuan 783 (48%) 479 (57%) 75 (64%) 69 (70%) 
Resided in lowlands for 
more than 1 year? (yes) 1,547 (95%) 797 (96%) 111 (95%) 93 (94%) 
Subdistrict 
 Banti 29 (2%) 18 (2%) 0 (0%) 0 (0%) 
 Harapan and Kwamki 
Lama 226 (14%) 124 (15%) 4 (3%) 2 (2%) 
 Inauga 183 (11%) 106 (13%) 5 (4%) 5 (5%) 
 Kamoro Jaya 107 (7%) 77 (9%) 12 (10%) 10 (10%) 
 Kadun Jaya, Kaugapu and 
Pigapu 108 (7%) 11 (1%) 23 (20%) 14 (14%) 
 Limau Asri, Iwaka, Mulia 
Kencana and Naena 
Muktipura 
55 (3%) 3 (0.4%) 15 (13%) 15 (15%) 
 Koperapoka 396 (24%) 127 (15%) 13 (11%) 12 (12%) 
 Timika Jaya, Kwamki and 
Kwamki Baru 383 (23%) 262 (31%) 16 (14%) 14 (14%) 
 Wonosari Jaya and 
Nawaripi 49 (3%) 39 (5%) 24 (21%) 23 (23%) 
 Karang Senang and 
Bhintuka 95 (6%) 67 (8%) 5 (4%) 4 (4%) 
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TABLE 3 
Percentage of respondents who reported receiving blood tests and antimalarials (including tablets and injections) by survey 
 Public Private Overall 
2005 2013 AOR 
(95% 
CI)* 
P value 2005 2013 AOR 
(95% 
CI)* 
P value 2005 2013 AOR (95% 
CI)* 
P value 
Percent of visits that 
resulted in a blood test 
for malaria 
76% 
(285/375) 
94% 
(64/68) 
– < 0.001 29% 
(148/519) 
97% 
(31/32) 
– < 0.001 48% 
(433/894) 
95% 
(95/100) 
25.42 (9.88–
65.42) 
< 0.001 
Percent of blood tests 
that were positive 
75% 
(213/285) 
94% 
(60/64) 
– < 0.001 84% 
(124/148) 
87% 
(27/31) 
– 0.790 78% 
(337/433) 
92% 
(87/95) 
3.11 (1.29–
7.47) 
0.012 
Percent receiving correct 
antimalarial after testing 
positive† 
32% 
(67/212) 
85% 
(50/59) 
15.94 
(6.84–
37.14) 
< 0.001 9% 
(11/124) 
52% 
(14/27) 
12.16 
(3.42–
43.28) 
< 0.001 23% 
(78/336) 
74% 
(64/86) 
15.71 (8.18–
30.18) 
< 0.001 
Percent receiving 
chloroquine after testing 
positive 
62% 
(133/212) 
0% 
(0/59) 
– < 0.001 43% 
(53/124) 
11% 
(3/27) 
– 0.002 55% 
(186/336) 
3% 
(3/86) 
– < 0.001 
Percent not receiving an 
antimalarial after testing 
negative 
98% 
(61/62) 
100% 
(3/3) 
– –‡ 86% 
(19/22) 
100% 
(4/4) 
– –‡ 95% 
(80/84) 
100% 
(7/7) 
– –‡ 
Percent not receiving an 
antimalarial if no blood 
test given 
64% 
(58/90) 
100% 
(4/4) 
– –‡ 52% 
(192/371) 
0% 
(0/1) 
– –‡ 54% 
(250/461) 
80% 
(4/5) 
– 0.383 
AOR = adjusted odds ratio; CI = confidence interval. 
* Multivariate logistic regression adjusted for age, sex, ethnicity, and household socioeconomic status if five or more observations. The Fisher’s exact if less than five 
observations (no AORs). 
† In 2005, local guidelines recommended antimalarial treatment with chloroquine plus sulphadoxine–pyramethamine for Plasmodium falciparum and chloroquine for 
Plasmodium vivax. In those patients with P. vivax (either alone or mixed) primaquine was also recommended. In 2013, correct treatment regimens were dihydoartemisinin-
piperaquine for all species of malaria plus primaquine in those with P. vivax infections (alone or mixed). Plasmodium malariae infections (N = 2) were excluded from this 
analysis. 
‡ 2013 data predicted the outcome perfectly. All individuals had the same level of outcome; hence, no statistical computations can be performed for the logistic regression—
no statistical output is given in software. 
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TABLE 4 
Reported antimalarial treatment of individuals by reported diagnosis 
 2005 (N = 336) 2013 (N = 86) 
 Private Public Overall Private Public Overall 
Plasmodium falciparum (N) 68 99 167 14 32 46 
 Percentage receiving any ACT (DHP) 0% (0) 1% (1) 1% (1) 50% (7) 97% (31) 
83% 
(38) 
 Percentage receiving any antimalarial 
without ACT 
88% 
(60) 
94% 
(93) 
92% 
(153) 36% (5) 
3% (1) 13% (6) 
 Percentage receiving unknown 
antimalarial 0% (0) 3% (3) 2% (3) 14% (2) 0% (0) 4% (2) 
 Percentage receiving primaquine (any 
dose) 
62% 
(42) 
82% 
(81) 
74% 
(123) 
71% 
(10) 
59% 
(19) 
63% 
(29) 
 Percentage receiving any treatment 94% 
(64) 
98% 
(97) 
96% 
(161) 
100% 
(14) 
100% 
(32) 
100% 
(46) 
 Percentage receiving no treatment 6% (4) 2% (2) 4% (6) 0% (0) 0% (0) 0% (0) 
Plasmodium vivax (N) 51 108 159 12 25 37 
 Percentage receiving any ACT 0% (0) 0% (0) 0% (0) 50% (6) 96% (24) 
81% 
(30) 
 Percentage receiving any antimalarial 
without ACT 
75% 
(38) 
94% 
(102) 
88% 
(140) 25% (3) 
0% (0) 8% (3) 
 Percentage receiving unknown 
antimalarial 
20% 
(10) 5% (5) 9% (15) 25% (3) 4% (1) 11% (4) 
 Percentage receiving primaquine (any 
dose) 
29% 
(15) 
81% 
(88) 
65% 
(103) 58% (7) 
72% 
(18) 
68% 
(25) 
 Percentage receiving any treatment 94% 
(48) 
99% 
(107) 
97% 
(155) 
100% 
(12) 
100% 
(25) 
100% 
(37) 
 Percentage receiving no treatment 6% (3) 1% (1) 3% (4) 0% (0) 0% (0) 0% (0) 
Mixed infections (N) 5 5 10 1 2 3 
 Percentage receiving any ACT 0% (0) 0% (0) 0% (0) 100% (1) 
50% (1) 67% (2) 
 Percentage receiving any antimalarial 
without ACT 
80% 
(4) 60% (3) 70% (7) 0% (0) 
0% (0) 0% (0) 
 Percentage receiving unknown 
antimalarial 0% (0) 40% (2) 20% (2) 0% (0) 
50% (1) 33% (1) 
 Percentage receiving primaquine (any 
dose) 
60% 
(3) 60% (3) 60% (6) 
100% 
(1) 
50% (1) 67% (2) 
 Percentage receiving any treatment 80% 
(4) 
100% 
(5) 90% (9) 
100% 
(1) 
100% 
(2) 
100% 
(3) 
 Percentage receiving no treatment 20% (1) 0% (0) 
10% 
(10) 0% (0) 
0% (0) 0% (0) 
ACT = antimalarial combination therapy; DHP = dihydroartemisinin-piperaquine. 
TABLE 5 
Reported direct, indirect, and total costs per individual taking treatment of fever over the entire fever episode in 
2014 United States dollars 
Category 
2005 (N = 834) 2013 (N = 99) P value* 
Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median 
(IQR) 
 
Total direct costs† 9.4 
(27.3) 1.9 (0.4–5.6) 
8.1 
(17.0) 
1.7 (1.0–
8.1) 
0.119 
Total indirect costs 44.2 
(51.0) 
32.8 (10.9–
60.1) 
33.8 
(40.1) 
18.2 (0.0–
54.6) 
0.006 
 Total cost to the individual taking treatment 
due to lost wages 
19.3 
(30.6) 
0.0 (0.0–
32.8) 
28.4 
(38.3) 
9.1 (0.0–
45.5) 
0.010 
Page 14 of 18 
 Total cost for companions 4.1 
(6.5) 
0.00 (0.0–
5.5) 
3.2 
(7.6) 
0.0 (0.0–
0.0) 
0.001 
 Total cost for caretaking 19.7 
(30.5) 
10.9 (0.0–
27.3) 
2.0 
(9.1) 
0.0 (0.0–
0.0) 
< 0.001 
 Total cost for substitute labor 1.1 
(6.5) 0.0 (0.0–0.0) 
0.2 
(1.8) 
0.0 (0.0–
0.0) 
0.072 
Total costs 53.5 
(65.3) 
33.8 (16.4–
66.7) 
41.9 
(44.3) 
27.3 (8.1–
64.7) 
0.104 
IQR = interquartile range; SD = standard deviation. 
* Mann–Whitney rank test. 
† Includes payments made by the household for all treatments including diagnostics and transport. 
SUPPLEMENTAL FIGURE 1. Tree plot of ownership by groups from poorest (black) to richest (lightest gray). A 
discriminant analysis of principal components used to construct these groupings. 
SUPPLEMENTAL TABLE 1 
Multivariable analysis of risk factors for febrile illness in the past month (N = 2,830) 
Variable OR (95% CI) P value AOR (95% CI) P value 
Gender  Female Reference – – – 
 Male 1.24 (0.85–1.82) 0.266 – – 
Age (years) 
 > 15 Reference – – – 
 5–14 1.08 (0.68–1.70) 0.746 – – 
 < 5 1.02 (0.61–1.69) 0.951 – – 
Pregnant 
 No Reference – – – 
 Yes 1.69 (0.51–5.55) 0.391 – – 
Household size 
 > 7 members Reference – Reference – 
 ≤ 7 members 2.11 (1.01–4.43) 0.048 2.00 (0.96–4.15) 0.062 
Household socioeconomic status 
 Richest Reference – – – 
 Fourth 0.68 (0.37–1.24) 0.211 – – 
 Middle 1.32 (0.78–2.23) 0.302 – – 
 Second 1.05 (0.61–1.80) 0.857 – – 
 Poorest 0.76 (0.39–1.47) 0.410 – – 
Ethnicity 
 Highland Papuan Reference – Reference – 
 Lowland Papuan 1.45 (0.74–2.84) 0.275 1.53 (0.79–2.97) 0.209 
 Non-Papuan 1.92 (1.08–3.40) 0.025 1.84 (1.05–3.26) 0.035 
Resided in lowlands > 1 year? 
 Yes Reference – – – 
 No 1.24 (0.54–2.84) 0.605 – – 
Individual sleeps under an insecticide-treated bednet? 
 No Reference – – – 
 Yes 1.27 (0.86–1.86) 0.226 – – 
AOR = adjusted odds ratio; CI = confidence interval; OR = odds ratio. The multiple logistic regression included 
variables that were significant (P < 0.05) in the univariate logistic regression. 
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SUPPLEMENTAL TABLE 2 
Changes in parasite prevalence by location (subdistrict) 
Subdistrict 
2005 2013 
Househol
d 
members 
Total 
parasitemi
c N (%) 
Species, n (%) 
Househol
d 
members 
Total 
parasitemi
c N (%) 
Species, n (%) 
Plasmodiu
m 
falciparum 
Plasmodium
a vivax 
Plasmodiu
m malariae 
Mixed 
infectio
n 
Plasmodiu
m 
falciparum 
Plasmodiu
m vivax 
Plasmodiu
m malariae 
Mixed 
infectio
n 
Banti 119 7 (6) 0 (0%) 7 (100%) 0 (0%) 0 (0%) 0 – – – – – 
Harapan 
and 
Kwamki 
Lama 
576 136 (24) 67 (49%) 56 (41%) 2 (2%) 11 (8%) 80 14 (18) 6 (43%) 4 (29%) 4 (29%) 0 (0%) 
Inauga 405 47 (12) 19 (40%) 23 (49%) 0 (0%) 5 (11%) 290 25 (9) 10 (40%) 14 (56%) 1 (4%) 0 (0%) 
Kamoro 
Jaya 
273 102 (37) 44 (43%) 24 (24%) 11 (11%) 23 
(23%) 
254 37 (15) 17 (46%) 14 (38%) 5 (14%) 1 (3%) 
Kadun 
Jaya, 
Kaugapu, 
and Pigapu 
285 35 (12) 10 (29%) 17 (49%) 2 (6%) 6 (17%) 198 60 (30) 29 (48%) 25 (42%) 1 (2%) 5 (8%) 
Limau 
Asri, 
Iwaka, 
Mulia 
Kencana, 
and Naena 
Muktipura 
111 5 (5) 3 (60%) 2 (40%) 0 (0%) 0 (0%) 330 27 (8) 17 (63%) 9 (33%) 1 (4%) 0 (0%) 
Koperapok
a 
726 100 (14) 42 (42%) 45 (45%) 1 (1%) 12 
(12%) 
517 58 (11) 27 (47%) 31 (53%) 0 (0%) 0 (0%) 
Timika 
Jaya, 
Kwamki, 
and 
Kwamki 
Baru 
1,045 133 (13) 68 (51%) 57 (43%) 1 (0.8%) 7 (5%) 695 60 (9) 17 (28%) 40 (67%) 2 (3%) 1 (2%) 
Wonosari 
Jaya and 
98 15 (15) 11 (73%) 4 (27%) 0 (0%) 0 (0%) 258 37 (14) 14 (38%) 16 (43%) 6 (16%) 1 (3%) 
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Nawaripi 
Karang 
Senang 
and 
Bhintuka 
252 54 (21) 26 (48%) 13 (24%) 7 (13%) 8 (15%) 173 30 (17) 12 (40%) 10 (33%) 5 (17%) 3 (10%) 
Total 3,890 634 (16) 290 (46%) 248 (39%) 24 (4%) 72 
(11%) 
2,795 348 (12) 149 (43%) 163 (47%) 25 (7%) 11 (3%) 
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